RxDoctor Payments DataLook up a doctor →

Andy Tran, MD

Clinical Cardiac Electrophysiology · Surprise, AZNPI 1295781029

Payments from drug & device makers

$135,686in general payments, 2019–2025

Across 789 payments — averaging $171.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$81K
  • Abbott$36K
  • Impulse Dynamics (USA) Inc.$8K
  • Biotronik Inc.$6K
  • Biosense Webster, Inc.$2K
  • Cardiva Medical, Inc.$584
  • plus $3K from 35 others

What the payments were for

  • Consulting fees$35,94729%
  • Speaking & faculty fees$68,75055%
  • Grants$1,6671%
  • Travel & lodging$1,3791%
  • Food & beverage$16,98514%
  • Education$2580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$135,686 in reported general payments places this provider in the 80th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

See all clinical cardiac electrophysiology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,381,543
Medicare patients
1,139
Services billed
11,877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban480$626,117
XareltoRivaroxaban114$153,734
FarxigaDapagliflozin Propanediol64$82,690
EntrestoSacubitril/Valsartan52$78,775
JardianceEmpagliflozin37$47,754
MultaqDronedarone Hcl17$34,468
Metoprolol Succinate592$12,716
Flecainide Acetate207$12,091
Repatha SureclickEvolocumab19$11,032
Dofetilide58$9,377
Diltiazem 12hr ErDiltiazem Hcl21$7,072
Propafenone Hcl ErPropafenone Hcl38$5,645
Amiodarone Hcl242$5,507
VascepaIcosapent Ethyl11$5,485
Valsartan115$4,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$345$626,117480 claims
Johnson & JohnsonXarelto$259$153,734114 claims
AstraZenecaFarxiga$28$82,69064 claims
NovartisEntresto$247$78,77552 claims
Boehringer IngelheimJardiance$38$47,75437 claims
Sanofi-aventis U.S. LLCMultaq$59$34,46817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

Other clinical cardiac electrophysiology in Surprise

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →